Skip to main content Back to Top
Advertisement

1/8/2020

Lorazepam Tablets

Products Affected - Description

    • Ativan tablet, Bausch Health, 1 mg, bottle, 100 count, NDC 00187-0064-01
    • Ativan tablet, Bausch Health, 1 mg, bottle, 1000 count, NDC 00187-0064-10
    • Lorazepam tablet, Major, 0.5 mg, bottle, 100 count, NDC 00904-6007-60
    • Lorazepam tablet, Major, 1 mg, unit-dose blister pack, 100 count, NDC 00904-6008-61
    • Lorazepam tablet, Mylan Institutional, 0.5 mg, unit-dose blister pack, 100 count, NDC 51079-0417-20 - discontinued
    • Lorazepam tablet, Mylan Institutional, 1 mg, unit-dose blister pack, 100 count, NDC 51079-0386-20 - discontinued
    • Lorazepam tablet, Mylan Institutional, 2 mg, unit-dose blister pack, 100 count, NDC 51079-0387-20 - discontinued
    • Lorazepam tablet, Teva, 0.5 mg, bottle, 100 count, NDC 00591-0240-01
    • Lorazepam tablet, Teva, 0.5 mg, bottle, 1000 count, NDC 00591-0240-10
    • Lorazepam tablet, Teva, 2 mg, bottle, 100 count, NDC 00591-0242-01
    • Lorazepam tablet, Teva, 2 mg, bottle, 500 count, NDC 00591-0242-05
    • Lorazepam tablet, Teva, 2 mg, bottle, 1000 count, NDC 00591-0242-10

Reason for the Shortage

    • Aurobindo refuses to provide availability information.
    • Leading has lorazepam tablet presentations available.
    • Major did not provide a reason for the shortage.
    • Mylan has discontinued all bottled presentations.
    • Mylan Institutional discontinued all unit-dose blister pack presentations.
    • Sandoz discontinued all lorazepam presentations.
    • Teva did not provide a reason for the shortage.

Available Products

    • Ativan tablet, Bausch Health, 0.5 mg, bottle, 100 count, NDC 00187-0063-01
    • Ativan tablet, Bausch Health, 2 mg, bottle, 100 count, NDC 00187-0065-01
    • Lorazepam tablet, Leading, 0.5 mg, bottle, 100 count, NDC 69315-0904-01
    • Lorazepam tablet, Leading, 0.5 mg, bottle, 500 count, NDC 69315-0904-05
    • Lorazepam tablet, Leading, 0.5 mg, bottle, 1000 count, NDC 69315-0904-10
    • Lorazepam tablet, Leading, 1 mg, bottle, 100 count, NDC 69315-0905-01
    • Lorazepam tablet, Leading, 1 mg, bottle, 500 count, NDC 69315-0905-05
    • Lorazepam tablet, Leading, 1 mg, bottle, 1000 count, NDC 69315-0905-10
    • Lorazepam tablet, Leading, 2 mg, bottle, 100 count, NDC 69315-0906-01
    • Lorazepam tablet, Leading, 2 mg, bottle, 500 count, NDC 69315-0906-05
    • Lorazepam tablet, Leading, 2 mg, bottle, 1000 count, NDC 69315-0906-10
    • Lorazepam tablet, Major, 0.5 mg, unit-dose blister pack, 100 count, NDC 00904-6007-61
    • Lorazepam tablet, Major, 1 mg, bottle, 100 count, NDC 00904-6008-60
    • Lorazepam tablet, Major, 2 mg, bottle, 100 count, NDC 00904-6009-60
    • Lorazepam tablet, Major, 2 mg, unit-dose blister pack, 100 count, NDC 00904-6009-61
    • Lorazepam tablet, Teva, 0.5 mg, bottle, 500 count, NDC 00591-0240-05
    • Lorazepam tablet, Teva, 1 mg, bottle, 100 count, NDC 00591-0241-01
    • Lorazepam tablet, Teva, 1 mg, bottle, 500 count, NDC 00591-0241-05
    • Lorazepam tablet, Teva, 1 mg, bottle, 1000 count, NDC 00591-0241-10

Estimated Resupply Dates

    • Bausch Health has Ativan 1 mg tablets on back order and the company cannot estimate a release date.
    • Major has lorazepam 0.5 mg tablets in 100 count bottles and 2 mg tablets in 100 count unit-dose packages in limited supply. The company estimates release dates for additional product in late-January 2020.
    • Teva has lorazepam 0.5 mg tablets in 1,000 count bottles and 2 mg tablets on intermittent back order and the company is releasing supplies as they become available.

Updated

Updated January 8, 2020 by Leslie Jensen, PharmD, Drug Information Specialist. Created October 4, 2018 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2020, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins